Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. Current monitoring methods, such as imaging scans, present limitations, prompting exploration of alternative biomarkers. This review comprehensively explores the role of circulating tumor DNA (ctDNA) in advanced melanoma, covering technical aspects, detection methods, and its prognostic and predictive value. Recent findings underscore ctDNA’s potential applications and implications in clinical practice. This review emphasizes the need for precise and dynamic biomarkers in melanoma care, positioning ctDNA as a promising blood-based tool for prognosis, treatment response, and resistance mechanisms. The technical nuances of ctDNA detection, association with melanoma mutations, and its role in guiding therapeutic decisions for immunotherapy and targeted therapy underscore its multifaceted utility, marking a paradigm shift in clinical decision-making and offering a promising trajectory for personalized and informed care in advanced melanoma.
皮肤黑色素瘤作为一种侵袭性恶性肿瘤，随着免疫检查点抑制剂和靶向疗法的引入，其临床管理已发生重大变革。目前影像学扫描等监测方法存在局限性，促使人们探索替代性生物标志物。本综述全面探讨循环肿瘤DNA在晚期黑色素瘤中的作用，涵盖技术原理、检测方法及其预后与预测价值。最新研究结果凸显了ctDNA在临床实践中的潜在应用价值。本文强调黑色素瘤诊疗需要精准动态的生物标志物，并将ctDNA定位为具有前景的血液检测工具，可用于预后评估、治疗反应监测及耐药机制分析。ctDNA检测的技术细节、与黑色素瘤基因突变的关联性，以及在指导免疫治疗和靶向治疗决策中的作用，共同彰显其多维度临床应用价值，标志着临床决策模式的转变，为晚期黑色素瘤的个体化精准诊疗开辟了崭新路径。
Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
肿瘤(癌症)患者之家